Related Experiment Video
Updated: Jul 19, 2026
07:32
Assessing Iron Deposition in the Brains of 5xFAD Mice by Perls'/DAB Staining
Published on: May 23, 2025
DNA oxidation in Alzheimer's disease
William R Markesbery1, Mark A Lovell
1Department of Pathology and Laboratory Medicine, University of Kentucky, Lexington, Kentucky 40536-0230, USA. wmark0@email.uky.edu
Antioxidants & Redox Signaling
|October 13, 2006
Summary
Oxidative DNA damage, including elevated 8-hydroxyguanine (8-OHG), is an early event in Alzheimer
Area of Science:
- Biochemistry
- Neuroscience
- Genetics
Background:
- Oxidative stress and DNA damage are implicated in aging and neurodegenerative diseases like Alzheimer's disease (AD).
- Reactive oxygen species can cause various DNA lesions, including oxidized base adducts, potentially leading to mutations and altered protein synthesis.
- Elevated levels of specific oxidized bases (8-hydroxyguanine, 8-hydroxyadenine) are observed in late-stage AD brains.
Purpose of the Study:
- To investigate the role of oxidative DNA damage in the early stages of Alzheimer's disease (AD).
- To determine if DNA damage is an initiating factor or a secondary consequence in AD pathogenesis.
Main Methods:
- Analysis of oxidized DNA base adducts, including 8-hydroxyguanine (8-OHG) and 8-hydroxyadenine (8-OHA), in nuclear and mitochondrial DNA.
- Examination of DNA from individuals with mild cognitive impairment (MCI), an early form of AD.
- Comparison of DNA damage markers in MCI and late-stage AD.
Main Results:
- Elevated levels of 8-hydroxyguanine (8-OHG), 8-hydroxyadenine (8-OHA), and 5,6-diamino-5-formamidopyrimidine were found in both nuclear and mitochondrial DNA of individuals with mild cognitive impairment (MCI).
- These findings suggest that oxidative DNA damage is present at the earliest detectable stage of AD.
- The presence of these adducts in MCI indicates that DNA damage is an early event in AD, not merely a late-stage phenomenon.
Conclusions:
- Oxidative damage to DNA is an early event in the pathogenesis of Alzheimer's disease (AD).
- The detection of elevated DNA adducts in mild cognitive impairment (MCI) supports the role of oxidative stress in the initial stages of AD.
- These findings highlight the importance of addressing oxidative damage in the context of AD prevention and treatment strategies.
Related Concept Videos
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...